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Objectives. This study sought to compare the impact of primary
coronary angioplasty and thrombolytic therapy for acute myocar-
dial infarction (AMI) on 1-month infarct size and microvascular
perfusion.
Background. The effect of the reperfusion strategies of primary
coronary angioplasty and thrombolytic therapy on microvascular
integrity still remains to be determined.
Methods. Sixty-two consecutive patients with a first AMI,
undergoing intravenous tissue-type plasminogen activator (t-PA)
therapy (32 patients, Group I) or primary angioplasty (30 pa-
tients, Group II), were studied. Only patients with 1-month
Thrombolysis in Myocardial Infarction (TIMI) flow grade 2 or 3
were selected for the study. Patients in whom primary angioplasty
was unsuccessful or those with clinical evidence of failed reperfu-
sion were excluded. Microvascular perfusion was assessed at 1
month by intracoronary injection of sonicated microbubbles.
Contrast score index (CSI) and wall motion score index (WMSI)
were derived using qualitative methods.
Results. At baseline there were no significant differences be-
tween groups for age, risk factors, time to hospital presentation,
Killip class on admission, prevalence of multivessel disease or
anterior infarct site, infarct area extension before reperfusion,
peak creatine kinase levels and postinfarction treatment. Con-
versely, significant differences between groups were found at
follow-up for percent residual infarct related-artery (IRA) steno-
sis (70 6 12 vs 36 6 14 [mean 6 SD], p 5 0.0001), CSI (1.02 6
0.4 vs. 1.49 6 0.5, p 5 0.0003) and WMSI (1.67 6 0.3 vs. 1.45 6
0.3, p 5 0.015). In particular, in the subset of patients with TIMI
grade 3 flow, a perfusion defect occurred in one or more segments
subtended by the IRA in 72% of Group I versus 31% of Group II
patients (p < 0.00001) and in 27% of Group I versus 8% of Group
II segments (p < 0.00001).
Conclusions. The present study shows, in a highly selected
cohort with successful IRA recanalization, that primary angio-
plasty is more effective than thrombolysis in preserving microvas-
cular flow and preventing extension of myocardial damage at
1-month after AMI.
(J Am Coll Cardiol 1998;31:338–43)
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Several large clinical trials (1,2) have definitively shown that
the primary goal of treatment for patients with evolving
myocardial infarction is the rapid and sustained restoration of
anterograde coronary blood flow throughout the infarct-
related artery (IRA).
In the past decade, important progress has been achieved in
both pharmacologic and mechanical techniques to obtain the
prompt restoration of full anterograde flow in the IRA. Recent
studies have confirmed that either primary percutaneous trans-
luminal coronary angioplasty (PTCA) or intravenous throm-
bolysis may improve in-hospital survival and patient prognosis.
Comparative studies between these two reperfusion strategies
(3,4) have shown that immediate PTCA is more effective than
thrombolysis in restoring patency and preventing IRA reocclu-
sion.
However, recent myocardial contrast echocardiographic
(MCE) data have suggested (5) that microvascular perfusion
may remain impaired despite restoration of flow in the previ-
ously occluded epicardial coronary artery (“no-reflow” phe-
nomenon). Therefore, coronary artery patency should not be
considered synonymous with microcirculatory reflow (6). The
reestablishment of tissue-level perfusion within the jeopar-
dized myocardium may be the ultimate goal of treatment for
patients with an evolving myocardial infarction. The MCE
assessment of microvascular integrity after reperfusion and 1
month later is a good predictor of the definitive infarct size and
also provides useful estimates on residual myocardial viability
(7–9).
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To our knowledge, no study to date has evaluated the
impact on microvascular integrity of different reperfusion
modalities for acute myocardial infarction (AMI). The purpose
of the present study was therefore to assess the extent of
myocardial perfusion defect and infarct size 1 month after IRA
recanalization by either intravenous thrombolysis or primary
PTCA.
Methods
Patients. The research protocol was approved by the Insti-
tutional Review Board of the University of Illinois at Chicago
Hospital and by the ethical committee of “La Sapienza”
University of Rome School of Medicine. The enrollment of
patients began on January 2, 1993 and ended on March 8,
1994. The study included 62 consecutive patients (14 women,
48 men, mean [6SD] age 56 6 8 years) who were admitted to
the coronary care unit within 6 h after the onset of AMI (ST
segment elevation $2 mm in two or more contiguous leads,
followed by significant enzyme release). Thirty-two patients
received intravenous tissue-type plasminogen activator (t-PA)
(Group I), and 30 patients underwent primary PTCA (Group
II). Blood samples were collected every 4 h for cardiac enzyme
determination. Patients were selected for this investigation if
they met the following inclusion criteria: 1) technically ade-
quate echocardiographic studies allowing the detection of the
entire left ventricular endocardial contour during cardiac
catheterization; 2) age ,75 years; 3) no contraindication to
thrombolytic therapy; 4) no previous AMI or coronary artery
bypass graft surgery; 5) stable clinical condition during the
hospital period, with no major clinical events; and 6) IRA
patency with Thrombolysis in Myocardial Infarction (TIMI)
(10) flow grade 2 or 3 at 1-month follow-up coronary angiog-
raphy. Patients in whom primary angioplasty was unsuccessful
or with clinical evidence of failed reperfusion after thrombol-
ysis (i.e., persistent chest pain or ,50% reduction of ST
segment elevation in association with peak creatine kinase
(CK) release occurring 12 h after the onset of therapy) (11)
were excluded. The choice between treatments was indepen-
dent of clinical characteristics of patients and coronary artery
disease severity and was dependent only on the availability of
the catheterization laboratory staff to perform emergency
PTCA. All selected patients subsequently developed Q waves
on the 12-lead surface electrocardiogram.
Treatment protocol. Each patient received intravenous ni-
troglycerin in a dosage aimed at reducing systolic blood
pressure to 110 mm Hg. Additional therapy was given on
indication only. Patients assigned to accelerated t-PA received
an intravenous bolus of 15 mg and then an infusion of
0.75 mg/kg body weight (up to 50 mg) over 30 min and
0.5 mg/kg (up to 35 mg) over the next 60 min, accompanied by
an intravenous heparin bolus of 5,000 IU and then 1000 IU/h,
with dose adjustment to maintain an activated partial throm-
boplastin time between two or three times the normal value for
at least 2 days (1,12). Patients assigned to PTCA were imme-
diately transported to the catheterization laboratory and un-
derwent coronary angiography. Once the culprit vessel was
identified, balloon PTCA was performed to establish patency.
Coronary artery cineangiography. Coronary angiography
and angioplasty were performed by standard procedure and
equipment. Left and right coronary arteries were imaged in
multiple views, including craniocaudal angulations. Follow-up
angiograms were obtained at 1 month. IRA identification was
based on electrocardiographic changes, angiographic appear-
ance of the artery and associated regional wall motion abnor-
malities. Significant coronary artery disease other than that in
the IRA was defined as $50% reduction in lumen diameter of
a major epicardial coronary artery or one of its major branches
in each of the two orthogonal projections. The anterograde
radiocontrast flow through the IRA was determined on coro-
nary angiography performed at 1 month using the TIMI
criteria (10). Collateral flow was scored according to the
classification of Rentrop et al. (13). The presence of grade 2 or
3 collateral flow was considered significant. Coronary angiog-
raphy and angioplasty data were collected and analyzed by
three experienced observers. Consensus on procedural success,
TIMI grade and extent of coronary artery disease and collat-
eral flow was reached in all cases.
Echocardiographic analysis. Two-dimensional echocardio-
graphic images were obtained before reperfusion and at
1-month follow-up by commercially available echocardio-
graphic instruments. Baseline images were used to assess the
initial extent of left ventricular dysfunction. Follow-up images
were paired with the corresponding baseline images and
directly compared to assess changes in regional function. The
left ventricle was examined using standard echocardiographic
views, and wall motion was scored for each segment using a
16-segment left ventricular model. A previously described
semiquantitative scoring system (14) (1 5 normal; 2 5 hypo-
kinesia; 3 5 akinesia; 4 5 dyskinesia) was used to analyze each
study. The wall motion score index (WMSI) within the infarct
bed was derived by averaging the scores from each segment
within the infarct territory.
All echocardiograms were analyzed independently by two
experienced observers (P.V., P.H.) who had no knowledge of
patient data or each other’s results. In the rare case of
disagreement, a third observer (L.A.) reviewed the study and
his judgment was binding. Our interobserver and intraobserver
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variability for semiquantitative analysis of wall motion abnor-
malities in patients with AMI is good (7,9,15–17).
Myocardial contrast echocardiography. Microvascular
perfusion was assessed at 1 month using MCE by intracoronary
injection of sonicated microbubbles. Contrast echocardiogra-
phy was performed using a previously described method
(7,9,18,19). In brief, 0.5 to 2 ml of sonicated contrast agent was
separately injected into the left main and right coronary
arteries after diagnostic coronary angiography during simulta-
neously performed transthoracic two-dimensional echocardi-
ography in multiple views. A commercially available sonicating
system was used (Heat Systems Ultrasonics). Gain settings
were optimized at the beginning of each study and kept
constant throughout the study. Microvascular perfusion was
assessed in the end-diastolic frame of the postinjection cycle
showing the best delineation between contrast-enhanced and
nonenhanced myocardium. The aforementioned 16-segment
model of the left ventricle was used to assign the following
contrast scores (7,9): 0 5 no enhancement; 0.5 5 patchy
enhancement; 1 5 homogeneous enhancement. The contrast
score index (CSI) for the infarct zone was calculated by
dividing the sum of the contrast scores for each segment within
the infarct bed by the number of infarct segments analyzed. In
case of disagreement over scoring, a consensus was reached
after open discussion.
Statistical analysis. Continuous baseline and outcome
variables are given as mean value 6 SD, whereas discrete
variables are given as absolute values and percentages. Com-
parison between continuous variables was performed using
two-tailed Student t test. Categoric variables were compared
using a conventional chi-square test. Fisher exact test was
applied if there was an expected cell value ,5. Differences for
single comparisons were considered significant at p , 0.05.
Results
Baseline clinical, angiographic and echocardiographic
data. Of 73 patients admitted to our coronary care unit during
the enrollment period with a first reperfused AMI and with an
adequate acoustic window, seven (five in Group I, and two in
Group II) were excluded because of unstable clinical condi-
tions during the hospital period and four (three in Group I,
one in Group II) because of IRA occlusion at 1-month
coronary angiography. The remaining 62 patients were en-
rolled in the study.
The culprit lesion was in the left anterior descending
coronary artery in 41 (66%) of 62 patients, the left circumflex
coronary artery in 6 (10%) and the right coronary artery in the
remaining 15 (24%). Multivessel coronary artery disease was
present in 24 patients (38%). Table 1 shows the baseline
characteristics of patients undergoing t-PA (Group I) or
primary PTCA (Group II). There was no significant difference
in terms of age, gender, risk factors, time to presentation,
Killip class on admission, prevalence of multivessel coronary
artery disease or anterior infarct site, WMSI at day 1, peak CK
and postinfarction treatment.
Influence of reperfusion modality on 1-month regional
function, myocardial perfusion and angiographic data. A
slight, nonsignificant reduction in infarct size from day 1 to day
30 was observed in the t-PA–treated group, whereas a signifi-
cant reduction in infarct area extension was observed in the
PTCA-treated group (p 5 0.009). Accordingly, contrast score
at 1 month was significantly lower in the t-PA group than in the
PTCA group (p 5 0.0003) (Table 1). In particular, a perfusion
defect was found in one or more segments supplied by the IRA
in 26 (81%) of 32 Group I patients versus 10 (33%) of 30
Group II patients (p , 0.00001); analysis by segment showed a
perfusion defect in 82 (37%) of 221 Group I segments versus
24 (15%) of 153 Group II segments (p , 0.00001).
At 1-month after coronary angiography, conservatively
treated patients showed a higher grade of residual IRA
stenosis (p 5 0.0001) and a lower prevalence of TIMI grade 3
reflow (Table 1).
Relation between coronary reflow and myocardial reflow at
1-month follow-up. Normal coronary angiography radiocon-
trast runoff through the IRA (TIMI grade 3 reflow) was found
in 40 (65%) of 62 patients. CSI was significantly higher in this
subset of patients than in the remaining 22 patients with TIMI
grade 2 reflow (1.48 6 0.39 vs. 0.67 6 0.25, p , 0.0001,
respectively).
Table 1. Baseline and 1-Month Characteristics of Patients With
Acute Myocardial Infarction Undergoing Intravenous Thrombolysis







Age (yr) 56 6 8 57 6 4 NS
Hypertension 8 (25%) 7 (23%) NS
Diabetes 5 (15%) 5 (16%) NS
Tobacco use 20 (62%) 18 (60%) NS
Time to presentation (h)* 4.1 6 1.1 4.0 6 1.3 NS
Killip class (day 1) 1.2 6 0.4 1.3 6 0.3 NS
Multivessel disease 12 (37%) 12 (40%) NS
Anterior MI 23 (72%) 20 (67%) NS
Peak CK (mg/dl) 4,320 6 2,210 4,146 6 2,460 NS
WMSI
Day 1 1.75 6 0.3 1.73 6 0.3 NS
Day 30 1.67 6 0.3 1.45 6 0.3 0.015
Contrast score index 1.02 6 0.4 1.49 6 0.5 0.0003
Residual IRA stenosis (%) 70 6 12 36 6 14 0.0001
TIMI grade 3 flow 18 (56%) 22 (73%) NS
Collateral channels after
treatment for MI
0 5 (16%) NS
Beta-blockers 9 (28%) 8 (26%) NS
Ca channel blockers 19 (59%) 20 (66%) NS
ACE inhibitors 8 (25%) 7 (23%) NS
*Time from onset of symptoms of myocardial infarction (MI) to presentation
in coronary care unit. Data presented are mean value 6 SD or number (%) of
patients. ACE 5 angiotensin-converting enzyme; Ca 5 calcium; CK 5 creatine
kinase; IRA 5 infarct-related artery; MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty; TIMI 5 Thrombolysis in
Myocardial Infarction; t-PA 5 tissue-type plasminogen activator; WMSI 5 wall
motion score index.
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Figure 1 shows the relation between myocardial perfusion
and coronary reflow in the t-PA–treated patients compared
with the angioplasty group. In the subset of patients with TIMI
grade 2 reflow, myocardial perfusion was similarly reduced in
both groups. In contrast, in the subset of patients with TIMI
grade 3 reflow, contrast score was significantly higher in the
angioplasty group (p , 0.0025). In particular, among patients
with TIMI grade 3 reflow, MCE showed no myocardial perfu-
sion in one or more segments subtended by the IRA in 72%
Group I versus 31% Group II patients (p , 0.00001) and in
27% Group I versus 8% Group II segments (p , 0.00001) (Fig.
2). Thus, microvascular perfusion seems more preserved at
1-month follow-up in angioplasty-treated patients only if TIMI
grade 3 reflow is achieved.
Discussion
Previous randomized trials (3,4) have shown that treatment
by primary PTCA rather than intravenous t-PA is an indepen-
dent predictor of survival in patients with high risk anterior
wall infarction and results in a lower rate of stroke and
recurrent myocardial ischemia. In particular, de Boer et al.
(20) recently demonstrated that primary PTCA results in a
smaller infarct size and a better preserved myocardial function
before hospital discharge than randomization to streptokinase
treatment.
The results of the present study extend previous observa-
tions and show that after successful IRA recanalization,
1-month tissue level perfusion and regional function are better
preserved after PTCA than after t-PA.
Coronary artery recanalization and microvascular integ-
rity. Mounting evidence (1,12) suggests that even with the
most aggressive regimens of current pharmacologic ap-
proaches (accelerated front-loaded t-PA), early complete
TIMI grade 3 reperfusion is achieved in only ;50% of
patients, whereas with primary PTCA, IRA patency with brisk
flow (TIMI grade 3) is restored in a higher proportion of
patients (3). Recent trials (1,21) have documented that TIMI
flow grade 2 may not be regarded as successful reperfusion
therapy. Thus, one of the major advantages of IRA mechanical
dilation is to achieve early and complete recanalization. How-
ever, recent studies of MCE, coronary angiography and
positron emission tomography have shown (5,22) that about
one-fourth to one-third of patients with an AMI had inade-
quate tissue perfusion (“no-reflow” phenomenon) despite an-
giographically successful coronary recanalization. In particular,
Ito et al. (23) found that a substantial MCE defect may be
observed in all patients with TIMI grade 2 reflow after
reperfusion and in 16% of patients with TIMI grade 3 reflow.
This microvascular dysfunction was previously documented in
patients with an AMI undergoing primary PTCA or intracoro-
nary thrombolysis. However, the prevalence of this phenome-
non in the subset of patients undergoing intravenous throm-
bolysis still remains to be determined.
In the present study in a highly selected cohort with similar
baseline characteristics, we evaluated the impact on microvas-
cular perfusion of primary PTCA and t-PA therapy for reper-
fusion after AMI. Our results show that the prevalence of
nonperfused segments and the extension of contrast defect at
1 month after reperfusion are higher in patients treated with
intravenous t-PA than in those treated with primary PTCA.
In agreement with Ito et al. (23), our data show more
extensive microvascular dysfunction at day 30 in the subset of
patients with TIMI grade 2 versus TIMI 3 reflow, independent
of the reperfusion strategy. However, the most important
finding of the present study is that 72% of patients in the
t-PA-treated group still exhibit microvascular dysfunction de-
spite normal radiocontrast runoff through the IRA compared
with 31% of patients in the PTCA group (Fig. 1). Thus, the
majority of patients treated conservatively showed at least one
nonperfused segment within the risk area at 1 month after
AMI, even if TIMI grade 3 reflow through the IRA was
reached.
Factors affecting tissue perfusion level. Several theories
may be postulated to explain the profoundly different impact
on microvascular flow of the two reperfusion strategies. First,
the amount of perfusion in infarcted tissue is dependent on
many complex, interrelated factors, including the extent of
Figure 1. Bar graphs showing relation between myocardial contrast
score index and quality of coronary reflow in patients treated with t-PA
therapy (open bars) versus PTCA (solid bars). Independent of reper-
fusion strategies, patients with TIMI grade 2 reflow had a higher grade
of microvascular dysfunction at 1-month. Conversely, when TIMI
grade 3 flow was achieved, patients treated more aggressively also
exhibited more preserved myocardial perfusion at follow-up.
Figure 2. Comparison of frequency of 1-month contrast defects be-
tween t-PA-treated and PTCA-treated patients in the subset with
TIMI grade 3 flow.
341JACC Vol. 31, No. 2 AGATI ET AL.
February 1998:338–43 EFFECT OF t-PA VS. PRIMARY PTCA ON MICROVASCULAR PERFUSION
collateral circulation before recanalization; residual stenosis
severity of the culprit artery; vasodilator reserve in the IRA
territory; time to recanalization; duration of ischemia, extent
of reperfusion injury and loading conditions (22–24).
The high grade residual coronary stenosis observed in our
conservatively treated patients may be a strong factor influenc-
ing the extent of microvascular dysfunction at follow-up. Even
after a clot has been effectively dissolved, the significant
residual stenosis in the culprit lesion may play a role in
restricting blood flow at rest, thus resulting in continuing
ischemia and even ongoing necrosis of the subserved myocar-
dial tissue. Previous studies (25) have suggested that clinical
outcome may be worse in patients with .50% stenosis after
thrombolysis than in those with low grade residual narrowing,
with an increased risk of ventricular dilation and death.
Second, even though all patients included in the study were
admitted to the emergency room within 6 h of symptom onset,
time to recanalization cannot be exactly assessed in the t-PA–
treated group. However, previous studies (1,12) showed a
90-min IRA patency rate (TIMI grade 2 or 3) ranging from
82% to 91% (mean 85%). The time to first balloon inflation in
our patients was no longer than 120 min, thus the time to
reperfusion would be similar in the two groups of patients.
Furthermore, to avoid the effects of unsuccessful IRA recan-
alization on microvascular integrity, patients were not random-
ized to the two reperfusion strategies, but were included in the
study if, at day 1, primary PTCA was effective and no clinical
evidence of failed reperfusion occurred after intravenous t-PA
and if at the time of tissue perfusion evaluation, the IRA artery
was still patent, with TIMI flow grade 2 or 3.
In conclusion, our study further supports the importance of
rapid restoration of a brisk flow, through mechanical removal
of the underlying residual coronary stenosis, to prevent micro-
vascular damage.
Microvascular integrity and functional recovery. Only few
comparative trials between primary PTCA and thrombolysis
have measured left ventricular function at predischarge, and
their results were discordant (20,26,27). No difference in this
variable was found between the two reperfusion strategies in
the Primary Angioplasty in Myocardial Infarction (PAMI)
trial (26), whereas in the Zwolle trial (27), both global and
regional function were better preserved after PTCA. Some
important differences in study design and population may
explain these conflicting data. In particular, left ventricular
ejection fraction was measured in a different proportion of
patients in the two trials, and the prevalence of anterior
infarct location was higher in the latter study (36% vs. 49%,
respectively).
In the present study, the extent of wall motion abnormali-
ties within the infarct territory was measured before reperfu-
sion and at day 30. The infarct size was similar in both groups
before recanalization, but a significant reduction in WMSI was
observed only in the PTCA group. The prevalence of anterior
myocardial infarction in our study was 69%. As previously
suggested (20), the effects on microvascular perfusion and left
ventricular function of rapid restoration of flow induced by
primary PTCA may be more pronounced in this high risk
population. The better preserved myocardial perfusion in the
angioplasty group may explain the greater infarct size reduc-
tion observed at follow-up. As previously shown by Ito et al.
(5), the restoration of myocardial blood flow through a rela-
tively preserved microcirculation may promote the salvage of
postischemic myocardium, whereas an inadequate tissue per-
fusion after successful reperfusion predicts poor functional
recovery.
Study limitations. The present report is based on data
from a highly selected cohort enrolled after strict inclusion
criteria. Accordingly, the results cannot necessarily be trans-
ferred to the treatment of patients with AMI in general
practice. In particular, because the patients were not randomly
assigned to the two treatments, no clinical or prognostic
information can be derived from this study. Previous large
trials have shown the advantages of primary PTCA over a more
conservative treatment for AMI as for the percent of IRA
patency and quality of coronary reflow. Conversely, the major
goal of the present study was to determine the influence of
different successful reperfusion modalities on microvascular
dysfunction. In our study, the majority of conservatively
treated patients showed at least one nonperfused segment
even when TIMI grade 3 reflow was reached; it is therefore
possible that in a larger, unselected population this difference
could be even more pronounced. Larger randomized trials are
necessary to assess the prognostic impact of our preliminary
data.
Clinical implications. In the present study, MCE was
performed 1 month after AMI because it has been shown (28)
that microvascular damage may partially recover during the
first weeks after infarction. We and others (5,7,8) have previ-
ously found that the extent of MCE-assessed perfusion at 1
month is closely related to the amount of viable myocardium
and plays an important role in later functional recovery. Thus,
the more preserved microvasculature detected at follow-up in
invasively-treated patients may have important clinical impli-
cations because the likelihood of functional recovery either
spontaneously or after coronary artery bypass graft surgery is
significantly higher in this subset of patients (7,8,29).
Contrast echocardiography is low cost and safe and can be
performed in the catheterization laboratory, with some addi-
tional time. With the introduction of second-generation con-
trast agents (30) able to produce myocardial contrast enhance-
ment after peripheral vein injection, more information may be
derived on the relation between new reperfusion strategies and
the extent of microvascular flow.
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